Citations

Showing 10 of 108119 citations.

Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer.
Han, Leona C., Shah, Nilay D. , Gross, Cary P. , Smaldone, Marc C., Tilburt, Jon C. , Trinh, Q.D., Karnes, R. Jeffrey , Ranasinghe, Weranja Kalana Bodhisiri, Sun, Maxine , Kim, Simon P. , Ranasinghe, Weranja , Ross, Joseph S. , Nguyen, Paul L. , Yu, James B.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16085-e16085

10.1200/jco.2014.32.15_suppl.e16085 Get It

Impact of beta-blocker medication use on prostate cancer survival: Results from a single-institution cancer registry.
Kohli, Manish , Nandy, Debashis, Tan, Winston , Tindall, Donald J., Pathak, Jyotishman , Breitenstein, Matthew K. , Kohli, Manish , Haley, Charlotte, Lee, Adam , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16064-e16064

10.1200/jco.2014.32.15_suppl.e16064 Get It

Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC).
Siegel, Adam, Lin, Amy , Friedlander, Terence W. , Hsieh, Andrew C. , Hang, Evelyn, Weinberg, Vivian, Ryan, Charles J. , Bryce, Alan H.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16042-e16042

10.1200/jco.2014.32.15_suppl.e16042 Get It

A phase 2 study of 99m Tc-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to hist
Slawin, Kevin M., Tenke, Péter , Joniau, Steven , Ellis, William J., Buzogány, István, Мишугин, С. В. , Stolz, Josef, Матвеев, В. Б. , Karnes, R. Jeffrey , Jarrard, David Frasier, Yuh, Bertram, Trabulsi, Edouard J. , Stambler, Nancy , Armor, Thomas, Israel, Robert J. , Joniau, Steven , Alekseev, B. Yа. , Klein, Eric A. , Študent, Vladimír , Scherr, Douglas S. , Babich, John W.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16003-e16003

10.1200/jco.2014.32.15_suppl.e16003 Get It

The effect of SETD2 mutation (mts) on histone 3 lysine 36 tri-methylation (H3K36me3) and correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) enrolled in COMPARZ.
D’Amelio, Anthony M., Hsieh, James J. , Souza, Paul L. de , Deen, Keith C., Langmuir, Peter, Liu, Yuan , Ho, Thai H. , Choueiri, Toni K. , Motzer, Robert J.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4583-4583

10.1200/jco.2014.32.15_suppl.4583 Get It

Phase II efficacy trial of pazopanib in non-clear cell metastatic renal cell carcinoma (PINCR trial).
Costello, Brian A. , Tan, Winston , Leibovich, Bradley C. , Castle, Erik P., Parker, Alexander S. , Dronca, Roxana , Qin, Rui , Ho, Thai H. , Kohli, Manish

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS4606-TPS4606

10.1200/jco.2014.32.15_suppl.tps4606 Get It

Loss of BAP1 and PBRM1 expression in non-clear cell renal cell carcinomas compared to clear cell renal cell carcinomas.
Serie, Daniel, Eckel‐Passow, Jeanette E. , Parasramka, Mansi, Cheville, John C. , Parker, Alexander S. , Ho, Thai H. , Kapur, Payal , Joseph, Richard W. , Brugarolas, James

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4529-4529

10.1200/jco.2014.32.15_suppl.4529 Get It

PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.
Fay, André P. , Gray, Kathryn P. , Song, Jiaxi , Carvo, Ingrid, Lampron, Megan E., Albigès, Laurence , Stanton, Melissa, Freeman, Gordon J. , Hirsch, Michelle S. , Callea, Marcella , Ho, Thai H. , McDermott, David F. , Atkins, Michael B. , Signoretti, Sabina , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4526-4526

10.1200/jco.2014.32.15_suppl.4526 Get It

Out-of-pockets costs for patients receiving targeted agents for metastatic renal cell carcinoma.
Kim, Simon P. , Gross, Cary P. , Abouassaly, Robert , Houten, Holly K. Van , Thompson, R. Houston, Smaldone, Marc C., Trinh, Q.D., Sun, Maxine , Han, Leona C., Shah, Nilay D. , Psutka, Sarah P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e15598-e15598

10.1200/jco.2014.32.15_suppl.e15598 Get It

Serum procarboxypeptidase combined with CA19-9 and accuracy of detection of pancreatic cancer.
Orlowski, Michelle A., Oberg, Ann L. , Petersen, Gloria M. , Topilow, Arthur A. , Gilvarg, Charles, Orlowski, Michelle, Bamlet, William R. , Chari, Suresh T. , Davis, John M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4118-4118

10.1200/jco.2014.32.15_suppl.4118 Get It